LivaNova (NASDAQ:LIVN) Given “Buy” Rating at Needham & Company LLC

by · The Cerbat Gem

Needham & Company LLC reaffirmed their buy rating on shares of LivaNova (NASDAQ:LIVN – Free Report) in a research report report published on Monday morning,Benzinga reports. Needham & Company LLC currently has a $75.00 price objective on the stock.

LIVN has been the subject of several other research reports. Mizuho decreased their price target on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, October 31st. Baird R W raised shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 17th. Robert W. Baird upped their price target on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. The Goldman Sachs Group started coverage on shares of LivaNova in a report on Friday, October 4th. They set a “buy” rating and a $65.00 price objective on the stock. Finally, StockNews.com lowered LivaNova from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 16th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, LivaNova has a consensus rating of “Buy” and an average price target of $69.17.

Read Our Latest Research Report on LIVN

LivaNova Trading Up 3.5 %

LIVN stock opened at $52.48 on Monday. LivaNova has a 12 month low of $42.75 and a 12 month high of $64.47. The firm’s 50-day moving average is $52.24 and its 200 day moving average is $52.30. The company has a market capitalization of $2.85 billion, a PE ratio of 124.95 and a beta of 1.01. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87.

Institutional Investors Weigh In On LivaNova

Several institutional investors have recently added to or reduced their stakes in the business. Point72 Asset Management L.P. grew its stake in LivaNova by 204.3% during the 2nd quarter. Point72 Asset Management L.P. now owns 1,285,636 shares of the company’s stock valued at $70,479,000 after purchasing an additional 863,157 shares during the last quarter. First Light Asset Management LLC increased its stake in shares of LivaNova by 591.1% in the second quarter. First Light Asset Management LLC now owns 710,390 shares of the company’s stock worth $38,944,000 after acquiring an additional 607,598 shares during the period. Great Lakes Advisors LLC purchased a new position in shares of LivaNova during the second quarter worth $16,614,000. Driehaus Capital Management LLC lifted its position in LivaNova by 64.7% during the second quarter. Driehaus Capital Management LLC now owns 544,042 shares of the company’s stock valued at $29,824,000 after purchasing an additional 213,749 shares during the period. Finally, Point72 DIFC Ltd boosted its holdings in LivaNova by 75,799.6% in the third quarter. Point72 DIFC Ltd now owns 181,400 shares of the company’s stock valued at $9,531,000 after purchasing an additional 181,161 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

About LivaNova

(Get Free Report)

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

See Also